Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289020 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1RECQLSMN1; SMN2HTT | |
| SCHEMBL8514348 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1RECQLSMN1; SMN2HTT | |
| SCHEMBL13754830 | 0.85 | KMO (0.50) | KDM4EALDH1A1SMN1; SMN2HTTPOLB | |
| SCHEMBL1186125 | 0.82 | HTT (0.44) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL1186128 | 0.82 | HTT (0.44) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL4901316 | 0.82 | CYP1A2 (0.49) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL7900930 | 0.82 | CYP1A2 (0.49) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL4901313 | 0.82 | CYP1A2 (0.49) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 | |
| SCHEMBL1919344 | 0.81 | HTT (0.51) | KDM4EALDH1A1SMN1; SMN2HTTPOLB | |
| SCHEMBL446955 | 0.81 | HTT (0.61) | ALDH1A1SMN1; SMN2HTTPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2661268-A2 | INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PTC THERAPEUTICS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | KDM4E 1910/4885ALDH1A1 4226/4885RECQL 88/4885 |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | KDM4E 1776/4885ALDH1A1 3559/4885RECQL 151/4885 |
| US-20080119473-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | KDM4E 1227/4885ALDH1A1 3402/4885RECQL 1300/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | KDM4E 1776/4885ALDH1A1 3559/4885RECQL 151/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | KDM4E 1953/4885ALDH1A1 4256/4885RECQL 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.